Lumos Diagnostics (ASX:LDX) Holdings Ltd CEO Doug Ward sits down with Jonathan Jackson to explore the company's innovative point-of-care diagnostic solutions. Lumos, known for its proprietary Lumos-branded diagnostic tests, has been making strides in healthcare technology, particularly with its FebriDx device, designed to revolutionise healthcare settings. Ward provides an insight into Lumos’ diverse technology and product suite, focusing on the FebriDx device's role in diagnosing and managing Acute Respiratory Infections (ARIs) efficiently. The discussion looks at the regulatory achievements and commercial trajectory of FebriDx on a global scale, highlighting the strategic advancements Lumos has made in the diagnostics field. Ward discusses the latest study published in the Infectious Diseases and Clinical Microbiology journal, which evaluated FebriDx’s efficacy in pediatric care. Conducted at Sant Joan de Déu Hospital in Barcelona, the study involved 216 paediatric patients and underscored FebriDx’s potential to optimise antibiotic usage in children with febrile respiratory infections. According to the study, FebriDx not only refines antibiotic administration but also reduces the reliance on chest X-rays, marking a significant step forward in managing paediatric febrile illnesses more effectively and safely.
Lumos Diagnostics’ breakthroughs in paediatric care with FebriDx
